Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activity.

ABSTRACT:

Background & aims

Diet and weight loss remain the primary treatment for most patients with metabolic dysfunction-associated fatty liver disease (MASLD), with one recent drug therapy approved for severe cases. However, a significant need remains for non-invasive tests (NITs) that can assist clinicians in evaluating treatment response. We aimed to explore the ability of several NITs to reflect a change of at least one point in histologic non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS).

Methods

This study explores biomarkers reflecting treatment response in 173 patients from secondary care with type 2 diabetes or severe obesity, all of whom underwent repeated liver biopsies and blood samples. We measured soluble triggering receptor expressed on myeloid cells 2 (T

SUBMITTER: Wernberg CW 

PROVIDER: S-EPMC12269582 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature